PET scanning in clinical oncology

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 353-355

  Timothy, A R ^a   Cook, G J R ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

BREAST CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; GERM CELL TUMOR; ISOTOPE LABELING; LYMPH NODE METASTASIS; LYMPHOMA; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TERATOMA;

EID: 0031779620     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008253213404     Document Type: Editorial

References (29)

1. Warburg O. On the origin of cancer cells Science 123 1954 306 314
2. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool Invest Radiol 22 1987 360 371
3. Ogawa T. Kanno I. Shishido F. Clinical value of PET with 18F fluorodeoxyglucose and L methyl-11C-methionine for the diagnosis of recurrent brain tumour and radiation injury Acta Radiol 32 1991 197 202
4. Dahlbom M. Hoffman E.J. Hoh C.K. Whole body positron emission tomography, part 1. Methods and performance characteristics J Nucl Med 33 1992 1191 1199
5. Gupta N.C. Frank A.L. Dewan N. Solitary pulmonary nodules: Detection of malignancy with PET 2-[F-18]-fluoro-2-deoxy-D-glucose Radiology 184 1992 441 444
6. Kubota K. Matsuzawa T. Fujiwara T. Differential diagnosis of lung tumour with positron emission tomography: A prospective study J Nucl Med 31 1990 1927 1932
7. Crowe J.P. Adler L.P. Shenk R. Positron emission tomography and breast masses; Comparison with clinical, mammographic and pathological findings Ann Surg Oncol 1 1994 1132 1140
8. Tse N.Y. Hoh C.K. Hawkins R.A. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease Ann Surg 216 1992 27 34
9. Adler L.P. Crowe J.P. al-Kaisi N.K. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-f1uoro-D-glucose PET Radiology 187 1993 743 750
10. Wilson C.B. Young H.E. Ott R.J. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: Prospects for detection and management Eur J Nucl Med 22 1995 508 513
11. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer Lancet 344 1994 1265 1266
12. Barrington S.F. Saunders C.A.B. Madan B. Can FDG-PET predict marrow involvement in patients with lymphoma J Nucl Med 38 1997 128P
13. 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases Ann Oncol 9 4 1998 397 401 (this issue)
14. Moog F. Bangerter M. Diederichs C.G. Lymphoma: Role of whole body 2-deoxy-2-[F-18]fiuoro-D-glucose (FDG) PET in nodal staging Radiology 203 1997 795 800
15. Hoh C.K. Glaspy J. Rosen P. Whole body FDG PET for staging of Hodgkins disease and lymphoma J Nucl Med 38 1997 343 348
16. Gritters L.S. Francis I.R. Zasadny K.R. Initial assessment of positron emission tomography using 2-fluorme-18-fluoro-2-deoxy-D-glucosc in the imaging of melanoma J Nucl Med 34 1993 1420 1427
17. Laubenbacher C. Saumweber D. Wagner-Manslau C. Comparison of fluorine-18-deoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinomas J Nucl Med 36 1995 1747 1757
18. Anzai Y. Carroll W.R. Quint D.J. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses Radiology 200 1996 135 141
19. Bailet J.W. Abemayor E. Jabour B.A. Positron emission tomography: A new. precise imaging modality for detection of primary head and neck tumours and assessment of cervical lymphadenopathy Laryngoscope 102 1992 281 288
20. Jansson T. Westlin J.E. Ahlstrom H. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13 1995 1470 1477
21. Wahl R.L. Zasadny K. Helvie M. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation J Clin Oncol 11 1993 2101 2111
22. Haberkorn U. Strauss L.G. Dimitrakopolou A. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy J Nucl Med 34 1993 12 17
23. Janicek M. Kaplan W. Neuberg D. Canellos G.P. Shulman L.N. Early restaging gallium scans predict outcome in poor prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy J Clin Oncol 15 1997 1631 1637
24. Strauss L.G. Conti P.S. The applications of PET in clinical oncology J Nucl Med 32 1991 623 648
25. Nuutinen J.M. Leskinen S. Elomaa I. Detection of residual tumours in postchemotherapy testicular cancer by FDG PET Eur J Cancer 33 1997 1234 1241
26. Stephens A.W. Gonin R. Hutchins G.D. Einhorn L.H. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients J Clin Oncol 14 1996 1637 1641
27. Valk P.E. Pounds T.R. Tesar R.D. Cost-effectiveness of PET imaging in clinical oncology Nucl Med Biol 23 1996 737 743
28. Adams S. Baum R. Rink T. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendoenne tumours Eur J Nucl Med 25 1998 79 83
29. Cook G.J.R. Fogelman I. Maisey M. Normal physiological and benign pathological variants of 18-f1uoro-2-dcoxyglucose positron emission tomography scanning: Potential for error in interpretation Semin Nucl Med 24 1996 308 314